US · RVMD · BIOTECHNOLOGY
Revolution Medicines, Inc. (RVMD) intrinsic value and stock valuation
$161.20as of 2026-11-21 · Mkt cap 41.95B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Revolution Medicines, Inc. DCF and intrinsic value
InvestorsCraft values RVMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RVMD’s statements →
Revolution Medicines, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Roivant Sciences Ltd. (ROIV) $38.66
- Moderna, Inc. (MRNA) $195.00
- BridgeBio Pharma, Inc. (BBIO) $76.03
- Ascendis Pharma A/S (ASND) $252.73
- Exelixis, Inc. (EXEL) $64.63
- Madrigal Pharmaceuticals, Inc. (MDGL) $379.10
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Summit Therapeutics Inc. (SMMT) $9.95
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M |
| Operating income | -$-1.18B | -$-689.52M | -$-487.19M | -$-258.28M | -$-188.01M |
| Net income | -$-1.13B | -$-600.09M | -$-436.37M | -$-248.71M | -$-187.09M |
| EPSd | -$-5.95M | -$-3.58M | -$-3.86M | -$-3.08M | -$-2.57M |
| Operating cash flow | -$-897.74M | -$-557.44M | -$-350.57M | -$-224.4M | -$-147.18M |
| Capital expenditure | -$-15.99M | -$-10.31M | -$-7.73M | -$-10.82M | -$-6.53M |
| Free cash flow | -$-913.73M | -$-567.74M | -$-358.3M | -$-235.22M | -$-153.71M |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738M |
| Total debt | $158.7M | $135.8M | $87.9M | $64.2M | $66.6M |
| Net debt | -$-225.04M | -$-407.22M | -$-608.2M | -$-97.21M | -$-41.86M |
| Total equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M |
| Cash and short-term investments | $2.03B | $2.29B | $1.85B | $644.9M | $577.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M |
| Cost of revenue | $16.6M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-16.56M | $0.00 | $11.6M | $35.4M | $29.4M |
| Research and development expenses | $978.7M | $592.2M | $423.1M | $253.1M | $187M |
| Selling, general and administrative expenses | $187.1M | $97.3M | $75.6M | $40.6M | $30.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.17B | $689.5M | $498.8M | $293.7M | $217.4M |
| Cost and expenses | $1.18B | $689.5M | $498.8M | $293.7M | $217.4M |
| Interest income | $90.7M | $86.9M | $47.5M | $9.15M | $930K |
| Interest expense | $24.2M | $0.00 | $300K | $0.00 | $10K |
| Depreciation and amortization | $16.6M | $11.8M | $9.31M | $9.66M | $7.33M |
| Ebitda | -$-1.09B | -$-589.02M | -$-430.28M | -$-239.47M | -$-179.75M |
| Operating income | -$-1.18B | -$-689.52M | -$-487.19M | -$-258.28M | -$-188.01M |
| Total other income/expenses, net | $51.1M | $88.7M | $47.3M | $9.15M | $920K |
| Income before tax | -$-1.13B | -$-600.85M | -$-439.89M | -$-249.12M | -$-187.09M |
| Income tax expense | $0.00 | -$-750K | -$-3.52M | -$-420K | $0.00 |
| Net income | -$-1.13B | -$-600.09M | -$-436.37M | -$-248.71M | -$-187.09M |
| Weighted average shares outstanding | $190.1M | $167.7M | $113.2M | $80.6M | $72.8M |
| Weighted average diluted shares outstanding | $190.1M | $167.7M | $113.2M | $80.6M | $72.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.03B | $2.29B | $1.85B | $644.9M | $577.1M |
| Net receivables | $0.00 | $0.00 | $1.25M | $4.67M | $5.93M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $2.08B | $2.33B | $1.88B | $660.2M | $589.8M |
| Property, plant and equipment, net | $165.3M | $141.8M | $100M | $73.7M | $71.2M |
| Goodwill and intangible assets | $70.4M | $71.3M | $72.4M | $73.4M | $74.5M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $279.5M | $230.7M | $182.4M | $151.8M | $148.2M |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738M |
| Accounts payable | $64.6M | $54.4M | $61.8M | $21.3M | $14.1M |
| Short-term debt | $16.5M | $12.9M | $7.37M | $6.77M | $6.21M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $4.46M | $12.4M |
| Total current liabilities | $290.4M | $163.9M | $143.9M | $62M | $60.4M |
| Long-term debt | $142.2M | $123M | $80.6M | $57.4M | $60.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $6.57M |
| Total non-current liabilities | $432.8M | $129.2M | $91.7M | $64.8M | $75.1M |
| Capital lease obligations | $16.5M | $135.8M | $87.9M | $64.2M | $66.6M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
| Common stock | $20K | $20K | $20K | $10K | $10K |
| Retained earnings | -$-2.87B | -$-1.74B | -$-1.14B | -$-701.34M | -$-452.64M |
| Accumulated other comprehensive income (loss) | $3.24M | $1.32M | $540K | -$-1.78M | -$-380K |
| Total equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M |
| Total investments | $1.64B | $1.75B | $1.16B | $483.5M | $468.6M |
| Total debt | $158.7M | $135.8M | $87.9M | $64.2M | $66.6M |
| Net debt | -$-225.04M | -$-407.22M | -$-608.2M | -$-97.21M | -$-41.86M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.13B | -$-600.09M | -$-436.37M | -$-248.71M | -$-187.09M |
| Depreciation and amortization | -$-26.96M | $11.8M | $9.31M | $9.66M | $7.33M |
| Stock-based compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M |
| Change in working capital | $86.8M | $1.17M | $40.7M | -$-13.49M | $8.72M |
| Accounts receivable | $0.00 | $1.25M | $3.42M | $1.26M | $460K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $7.68M |
| Accounts payable | $9.54M | -$-6.46M | $32.5M | $7.29M | $2.24M |
| Net cash provided by operating activities | -$-897.74M | -$-557.44M | -$-350.57M | -$-224.4M | -$-147.18M |
| Investments in property, plant and equipment | -$-15.99M | -$-10.31M | -$-7.73M | -$-10.82M | -$-6.53M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $13.3M | $135.6M |
| Net cash used for investing activities | $118.1M | -$-554.39M | -$-342.6M | -$-24.12M | -$-142.12M |
| Common stock issued | $377.1M | $959.1M | $392.4M | $298.1M | $291.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $621.5M | $959.4M | $1.23B | $301.4M | $294.2M |
| Net change in cash | -$-158.16M | -$-153.08M | $534.7M | $52.9M | $4.88M |
| Cash at end of period | $388.6M | $543.1M | $696.2M | $163.2M | $110.2M |
| Operating cash flow | -$-897.74M | -$-557.44M | -$-350.57M | -$-224.4M | -$-147.18M |
| Capital expenditure | -$-15.99M | -$-10.31M | -$-7.73M | -$-10.82M | -$-6.53M |
| Free cash flow | -$-913.73M | -$-567.74M | -$-358.3M | -$-235.22M | -$-153.71M |
Line items
Line items
Line items
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Beta
- 1.38
Explore
Frequently asked questions
What is the intrinsic value of Revolution Medicines, Inc. (RVMD)?
InvestorsCraft does not currently publish an intrinsic value for RVMD. How the IC value is calculated.
Is RVMD undervalued?
InvestorsCraft does not publish an undervaluation signal for RVMD at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.